论文部分内容阅读
目的:对鲍曼不动杆菌感染的临床特征和耐药性进行分析,为临床诊治提供参考。方法:对2005年1月~2006年6月我院临床分离的共107株鲍曼不动杆菌通过琼脂对倍稀释法进行MIC测定;同时对相应的临床病例进行回顾性分析。结果:107株鲍曼不动杆菌大多分离自痰液,主要来自于ICU病房;且91.59%的患者同时存在2种以上基础疾病。鲍曼不动杆菌对氨曲南耐药率最高,为89.72%,依次是头孢西丁(87.85%),头孢哌酮(76.64%)、哌拉西林(69.16%)、头孢噻肟(65.42%)、环丙沙星(65.42%)、阿米卡星(56.07%)、头孢他定(55.14%)等。结论:我院鲍曼不动杆菌耐药情况严重,治疗首选碳青霉烯类抗生素,其次可选用头孢吡肟、头孢哌酮/舒巴坦。
Objective: To analyze the clinical features and drug resistance of Acinetobacter baumannii infection and provide reference for clinical diagnosis and treatment. Methods: A total of 107 strains of Acinetobacter baumannii isolated from our hospital from January 2005 to June 2006 were determined by agar dilution assay and the corresponding clinical cases were retrospectively analyzed. Results: Most of 107 Acinetobacter baumannii isolated from sputum mainly came from ICU ward, and 91.59% patients had more than two kinds of underlying diseases at the same time. Acinetobacter baumannii had the highest resistance rate to aztreonam, which was 89.72% followed by cefoxitin (87.85%), cefoperazone (76.64%), piperacillin (69.16%) and cefotaxime (65.42% ), Ciprofloxacin (65.42%), amikacin (56.07%) and ceftazidime (55.14%). CONCLUSION: Acinetobacter baumannii in our hospital has a serious drug resistance. The treatment is the preferred carbapenem antibiotic, followed by cefepime and cefoperazone / sulbactam.